BioCryst Pharmaceuticals Inc. (BCRX) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $8.24 (-2.66% 1D, market cap $2.16B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, BCRX ranks #106 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BCRX carries a Roarable C+ (67/100 RQD), trailing P/E of 8.3x, gross margin of —, and ROIC of 85.0%. By comparison, VCEL (Vericel Corporation) holds a D+ grade (58/100 RQD, P/E 133.0x, ROIC 3.4%, cap $2.06B) and MESO (Mesoblast Limited) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $1.97B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).
Per BCRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000882796), BioCryst Pharmaceuticals Inc. generated $954.8M in revenue (+13308.9% YoY), $263.9M in net income, and $347.4M in free cash flow against $514.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 36.4% FCF Margin ($347.4M FCF) & 52% Gross Margin
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
Macro rate sensitivity & RSI-14 (54.5) create a -11 pt regime headwind
Even with a 67/100 (C+) score, BCRX faces multiple-compression risk if 8.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($8.59) or 200D SMA ($8.76) invalidates the momentum regime and cuts Target Base ($8.57) toward Bear Floor ($6.68).
BioCryst Pharmaceuticals Inc. (BCRX) dropped -2.66% to $8.24, trading at 40% of its 52-week range ($6.23 – $11.22). Solid steady margins (85% return on capital), mixed timing at 8x P/E—hold if owned, no rush to chase.
Yahoo Finance report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
The consensus price target hints at a 137.9% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could me
Pacira BioSciences (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +13308.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BCRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BCRX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, BioCryst Pharmaceuticals Inc. (BCRX) ranks #106 by composite RQD confidence (67/100, grade C+) and #242 by equity capitalization ($2.16B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BCRX currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BCRX
ACTIVE
BioCryst Pharmaceuticals Inc. | C+ | 67/100 | 8.3x | — | 85.0% | -2.66% | $2.16B | Benchmark Subject |
| VCEL Vericel Corporation | D+ | 58/100 | 133.0x | 74.4% | 3.4% | +0.62% | $2.06B | /vcel-vs-bcrx → |
| MESO Mesoblast Limited | D | 51/100 | — | — | — | -4.09% | $1.97B | /meso-vs-bcrx → |
| RXRX Recursion Pharmaceuticals Inc. | D- | 40/100 | — | 5.0% | -35.0% | -4.96% | $2.41B | /rxrx-vs-bcrx → |
| COAG Hemab Therapeutics Holdings Inc. | C- | 59/100 | — | — | — | -0.65% | $1.94B | /coag-vs-bcrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioCryst Pharmaceuticals Inc. (BCRX) reported GAAP revenue of $954.8M (+13308.9% vs. FY2024 revenue of $7.1M , and +228.8% cumulative change since FY2023) , GAAP net income of $263.9M, operating cash flow of $347.4M, and free cash flow of $347.4M (+767.8% YoY). On the balance sheet, BCRX closed FY2025 with $514.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $954.8M | $263.9M | $347.4M | $347.4M | $514.2M | $0 |
| FY2024 (FY) | 2024-12-31 | $7.1M | -$88.9M | -$52.0M | -$52.0M | $490.4M | $314.9M |
| FY2023 (FY) | 2023-12-31 | $290.4M | -$226.5M | -$95.1M | -$95.1M | — | — |
As of 2026-11-03, BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $8.24 (-2.66% 1D, market cap $2.16B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, BCRX ranks #106 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BCRX carries a Roarable C+ (67/100 RQD), trailing P/E of 8.3x, gross margin of —, and ROIC of 85.0%. By comparison, VCEL (Vericel Corporation) holds a D+ grade (58/100 RQD, P/E 133.0x, ROIC 3.4%, cap $2.06B) and MESO (Mesoblast Limited) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $1.97B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).
Per BCRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000882796), BioCryst Pharmaceuticals Inc. generated $954.8M in revenue (+13308.9% YoY), $263.9M in net income, and $347.4M in free cash flow against $514.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
BCRX last traded at $8.24 (-2.66% on volume of 4,090,453 shares), positioning the stock -4.07% below its 50-day simple moving average ($8.59) and -5.94% below its 200-day simple moving average ($8.76). Across its 52-week range of $6.23 to $11.22, BCRX sits at the 40.3% percentile with a 14-day RSI of 54.5 (NEUTRAL RANGE) and an implied next-earnings move of ±7.7% ($7.61 to $8.87).
BioCryst Pharmaceuticals Inc. (BCRX) earns a live Roarable RQD composite score of 67/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $8.24 (-2.66% 1D, market capitalization $2.16B).
BioCryst Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The market capitalization is $2.2B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BioCryst Pharmaceuticals Inc. (BCRX) reported $954.8M in annual revenue (up from $7.1M in FY2024, +13308.9% YoY) and $263.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($290.4M revenue, -$226.5M net income) through FY2025, BCRX scaled operating cash flow to $347.4M and free cash flow to $347.4M, backed by $514.2M in total assets against $0 in total debt.
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), BCRX carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for BioCryst Pharmaceuticals Inc. (BCRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering BioCryst Pharmaceuticals Inc. (BCRX) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on BCRX here at $8.47: Fundamental cash engine scores 18 of 20 with ROIC at 85% and a 15.96% FCF yield while the stock trades at 8.3x TTM earnings.. Compare BCRX's 0.0% operating margin and 85.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $8.05 are getting bought.
@RiskArb_Desk Shorting a 10/20 institutional whale-flow stock at $8.47 is dangerous when funds are rotating into Health Care.
Careful chasing BCRX at $8.47. Macro regime fit scores only 9 of 20 and whale/13F flow scores 10 of 20, leaving institutional support and sector alignment as clear weak points.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $6.78 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: